ASENT2021

PRESIDENTIAL SYMPOSIUM: COVID and the nervous system as a basis medical and therapeutic challenge

Symposium to cover 1918 flu pandemic, the 2020 covid-19 pandemic and neurological consequences.   Stroke, olfactory (anosmia) and gustatory deficits  and other neurological complications result from covid-19 infection. The delayed appearance of postencephalitic Parkinsonism in people surviving the 1918 flu and those contracting encephalitis lethargica around the same time indicate hidden, protracted risks may await those who survie viral pandemics.  These topics and an update of neurological complications of covid-19 will be reviewed in this symposium.

FACULTY

10:00am – 10:30am

KEYNOTE PRESENTATION:

Neurological Consequences of Viral Pandemics including COVID-19 | Avindra Nath, MD, National Institute of Neurological Disorders and Stroke

10:30am – 10:40am

Live Q&A with KEYNOTE SPEAKER

10:40am – 10:45am

BREAK

10:45am – 11:05am

Invited Speaker

11:05am – 11:25am

Invited Speaker

11:25am – 11:35am

Live Faculty Panel Discussion and Q&A

11:35am – 11:45am

BREAK

Obstacles and Opportunities in Alzheimer’s Disease Neurotherapeutics

RNA editing and CRISPR technology: basic approaches and treatment implications for neurologic disease

Speakers will address barriers to success, the use of natural history and investigation of drug repurposing in the search for solutions in Alzheimer’s Disease neurotherapeutics.

Discussion of RNA editing as an improvement to CRISPR-related DNA editing, Molecular mechanims, clinical potentials of genome editing systems, applicability in neurological disorders.

FACULTY

FACULTY

11:45am – 12:05pm

Advances in Alzheimer’s Disease and Related Dementia Research | Eliezer Masliah, MD, National Institute on Aging

Lloyd Mitchell

12:05pm – 12:25pm

Leveraging Dominantly Inherited Alzheimer Disease for Current and Future Alzheimer Therapeutics | Eric McDade, DO, Washington University School of Medicine in St. Louis

TBD

12:25pm – 12:45pm

Barriers to success /opportunities in Alzheimer’s on the basis of prior or forthcoming trials | Dennis Selkoe, MD, Harvard Medical School and Brigham and Women’s Hospital

TBD

12:45pm – 1:00pm

Live Faculty Panel Discussion and Q&A

1:00pm – 1:15pm

Closing comments from ASENT President

Leveraging Unconventional (Big) Clinical Datasets for Treatment in Epilepsy

Dystonia: Genetics, pathophysiology, new targets and treatment

There is vast amount of data generated in the modern clinical practice of epilepsy, which is now more accessible than ever with the tools of Big Data. In this symposium, we will explore some of the efforts to tap this vast trove to advance the treatment of patients with epilepsy.

Genetics, pathophysiology, new targets, treatment; looked at it from 3 different ways

FACULTY

FACULTY

10:00am – 10:20am

Natural Language Processing of EEG Reports to Learn Seizure Onsets | Christopher Lee-Messer, MD, PhD, Stanford University

Dystonia Genes & Mechanisms | Hyder A. (Buz) Jinnah, MD, Emory School of Medicine

10:20am – 11:40am

Discovering Genotype-Phenotype Correlations Hidden in the EMR | Colin Ellis, MD, Children’s Hospital of Philadelphia

Pathophysiology in Dystonia | Mark Hallett, MD, National Institute of Neurological Disorders and Stroke

10:40am – 11:00am

Applying artificial intelligence to epilepsy care: from scanner to bedside | Ezequiel Gleichgerrcht, MD, PhD, Medical University of South Carolina

New Targets and Treatments in Dystonia | Susan Fox, MB ChB, MRCP, PhD, University of Toronto

11:00am – 11:15am

Live Faculty Panel Discussion and Q&A

Live Faculty Panel Discussion and Q&A

11:15am – 11:30am

BREAK

PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline

11:30am – 12:30pm

6 presentations each day/10 minutes each

12:30pm – 12:45am

Live Faculty Panel Discussion and Q&A

12:45pm – 1:00pm

Closing comments from ASENT President

Physiological markers and epigenetic risk factors in neurodegenerative disorders

Emerging therapeutics in NeuroOncology

This session will cover the physiological markers of stress and aging, epigenetic regulation of myelination and demyelination, and MS susceptibility variants exert local and distal effects on the T cell epigenome.

Glioblastoma Multiforme (GBM) is one of the most common and particularly aggressive forms of brain tumors of primarily glial cell origin. GBM is an incurable disease with few treatment advances for many years. Speakers will discuss new potential treatments and development in the field of GBM and other neuro-oncology diseases

FACULTY

FACULTY

Multiple sclerosis susceptibility variants exert local and distal effects on the T cell epigenome | Philip deJager, MD, PhD, Columbia University

New horizons for TTFields in neuro-oncology | Moshe Giladi, PhD, MBA, Novocure, Ltd.

Physiological markers of stress and aging | David Ziegler, PhD, University of California, San Francisco

Selinexor, Selective Inhibitor of Nuclear Export (SINE) compound in neuro-oncology | Paul Duic, MD, Karyopharm

Epigenetic regulation of myelination and remyelination | Patrizia Casaccia, MD, PhD, Icahn School of Medicine

Using the Mayo GBM PDX collection as a platform for developing novel combination therapies for GBM |  Jann Sarkaria, MD, Mayo Clinic

PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline

6 presentations each day/10 minutes each

Brain Organoids as Models of Neurological Disorders and Treatment

Parkinson’s Disease New Approaches

Speakers will describe the technology behind creating three-dimensional cell clusters that resemble peripheral and central nervous tissue, and how these CNS and PNS models show phenotypes consistent with CNS tissue, and diseases that plagued donors of the progenitor cells used to make these cell systems. The use of organoids to evaluate known and novel therapeutic agents, including gene therapies, will also be shown.

Speakers will look at Stem cells, C-ABL therapy, Exercise in the context of Parkinson’s Disease therapeutic gaps and developments.

FACULTY

FACULTY

Modelling physiology and disease with brain organoids | Thomas Hartung, MD, Johns Hopkins University

Stem cells therapy in Parkinson’s Disease |
Howard Federoff, MD, PhD, Aspen Neuroscience

Gaia Skibinski, PhD, System1 Biosciences

Disease modification of Parkinson’s Disease through oral kinase inhibitor therapy | Milton Werner, PhD, Inhibikase Therapeutics

Emily Lee, PhD, National Institute on Aging

Therapeutically Beneficial Effects of Exercise on Parkinson’s Disease | Daniel Corcos, PhD, Northwestern Medicine

PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline

6 presentations each day/10 minutes each